Mon. Nov 11th, 2024

Novartis Kisqali Gets Positive Chmp Opinion For Reducing Recurrence In Breast Cancer

ByLisa Luckas

10/18/2024
nude woman figurine
  • Novartis’ Kisqali receives positive CHMP opinion for reducing recurrence risk in HR+/HER2- early breast cancer, potentially doubling eligible patients for adjuvant treatment in Europe.
  • Based on Phase III NATALEE trial, Kisqali with endocrine therapy reduced recurrence risk by 25%. The decision follows FDA approval and supports Kisqali’s use in a broad patient population, including high-risk node-negative cases.
  • Final EC decision expected in two months.

Fri Oct 18 11:52:03 -2024 UTC– Novartis receives positive CHMP opinion for Kisqali® for adjuvant treatment of HR+/HER2- early breast cancer.

Kisqali reduces recurrence risk by 25% in Phase III NATALEE trial, targeting a broad patient population. Approval may expand adjuvant therapy options in Europe.

Breast cancer is a common diagnosis, with Kisqali showing promise in reducing recurrence rates. Kisqali’s potential benefits are emphasized, awaiting final EC decision within two months.

Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:

About Lisa

Subscribe to Lisa’s Newsletter today!

Keep Up: Nobot.News Launches Breaking Newsletter

Read more Business News as it happens!

Business

FDA Approval for Novartis.
AstraZenca also invests in Breast Cancer.

ByLisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *